COMMON QUESTIONS
The questions readers and answer engines ask most about CMLase, answered from the published record — with the limits of that record stated as plainly as the results.
CMLase is the name used for an engineered enzyme designed to recognise Nε-carboxymethyl-lysine (CML) modifications located on proteins. The reported research enzyme, CrGO-897, was developed from a glycine-oxidase scaffold through computational design, screening and directed evolution. Under controlled laboratory conditions, the enzyme was shown to convert protein-associated CML back into lysine.
CML — Nε-carboxymethyl-lysine — is a stable advanced glycation end-product: a modification of lysine residues that accumulates on long-lived proteins as tissues age, where it acts as a ligand for the receptor for advanced glycation end products (RAGE). In this context CML has nothing to do with chronic myeloid leukaemia, which shares the abbreviation.
The original CrGO-897/CMLase enzyme was reported by external researchers at Revel Pharmaceuticals, Calico Life Sciences and the University of Colorado Anschutz Medical Campus, in a peer-reviewed paper published in Nature Communications in July 2026. Panacea Bio Chem Ltd did not invent the original enzyme and does not claim authorship or ownership of that original discovery.
In controlled laboratory systems the enzyme removed CML from model proteins and restored the affected residue to lysine. On isolated human lens proteins from a 64-year donor, measured CML was reduced by 45% (LC-MS/MS) and 78% (ELISA). In prepared human abdominal aorta from a 75-year donor, measured CML was reduced by more than 70%, and in prepared human skin from donors aged 20–75 years by approximately 55%. Every tissue result was obtained ex vivo, in homogenates or thin prepared sections; no living-organism study was performed.
No. CMLase reverses one specific chemical modification — the CML adduct — under laboratory conditions and in prepared human tissue samples. It is not currently shown to reverse every advanced glycation end-product, every protein cross-link or ageing as a whole, and no effect on overall ageing has been established. It is not reported to break glucosepane cross-links.
No. The published evidence is in vitro and ex vivo — homogenates and thin prepared tissue sections — with no administration to any living organism. As of registry probes run on 8 September 2026, ClinicalTrials.gov records no registered trial of CMLase, of CrGO-897, or of any deglycating enzyme.
No. CMLase is a research-stage enzyme described in the peer-reviewed literature. It remains experimental, is not an approved medical treatment, and is not available for clinical or consumer use.
Panacea Bio Chem Ltd, led by Bogdan Dicoias, conducts an independent research programme around enzymatic protein repair, enzyme stabilisation, formulation, preservation, delivery and related molecular-repair technologies — the engineering problems that sit between a laboratory proof of concept and any future therapeutic translation. The programme claims direction, not results.